251 related articles for article (PubMed ID: 27379819)
1. Utilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine Use Disorder.
Mooney LJ; Hillhouse MP; Thomas C; Ang A; Sharma G; Terry G; Chang L; Walker R; Trivedi M; Croteau D; Sparenborg S; Ling W
J Addict Med; 2016; 10(4):236-43. PubMed ID: 27379819
[TBL] [Abstract][Full Text] [Related]
2. Medication Adherence Monitoring Using Smartphone Video Dosing in an Open-label Pilot Study of Monthly Naltrexone Plus Once-daily Bupropion for Methamphetamine Use Disorder: Feasibility and Acceptability.
Walker R; Hillhouse M; Perrochet B; Sparenborg S; Mooney L; Ling W
J Addict Med; 2019; 13(5):372-378. PubMed ID: 30724759
[TBL] [Abstract][Full Text] [Related]
3. Bupropion and Naltrexone in Methamphetamine Use Disorder.
Trivedi MH; Walker R; Ling W; Dela Cruz A; Sharma G; Carmody T; Ghitza UE; Wahle A; Kim M; Shores-Wilson K; Sparenborg S; Coffin P; Schmitz J; Wiest K; Bart G; Sonne SC; Wakhlu S; Rush AJ; Nunes EV; Shoptaw S
N Engl J Med; 2021 Jan; 384(2):140-153. PubMed ID: 33497547
[TBL] [Abstract][Full Text] [Related]
4. Impact of prospectively determined A118G polymorphism on treatment response to injectable naltrexone among methamphetamine-dependent patients: an open-label, pilot study.
Pal R; Mendelson JE; Flower K; Garrison K; Yount G; Coyle JR; Galloway GP
J Addict Med; 2015; 9(2):130-5. PubMed ID: 25622123
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of the naltrexone/bupropion combination for the treatment of obesity: an update.
Christou GA; Kiortsis DN
Hormones (Athens); 2015; 14(3):370-5. PubMed ID: 26188223
[TBL] [Abstract][Full Text] [Related]
6. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.
Krupitsky E; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Silverman BL
Addiction; 2013 Sep; 108(9):1628-37. PubMed ID: 23701526
[TBL] [Abstract][Full Text] [Related]
7. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
[TBL] [Abstract][Full Text] [Related]
8. Naltrexone plus bupropion reduces cigarette smoking in individuals with methamphetamine use disorder: A secondary analysis from the CTN ADAPT-2 trial.
Schmitz JM; Stotts AL; Yoon JH; Northrup TF; Villarreal YR; Yammine L; Weaver MF; Carmody T; Shoptaw S; Trivedi MH
J Subst Use Addict Treat; 2023 Aug; 151():208987. PubMed ID: 36822269
[TBL] [Abstract][Full Text] [Related]
9. Extended observation of reduced methamphetamine use with combined naltrexone plus bupropion in the ADAPT-2 trial.
Li MJ; Chau B; Belin T; Carmody T; Jha MK; Marino EN; Trivedi M; Shoptaw SJ
Addiction; 2024 Jun; ():. PubMed ID: 38856086
[TBL] [Abstract][Full Text] [Related]
10. A Phase 4, Pilot, Open-Label Study of VIVITROL® (Extended-Release Naltrexone XR-NTX) for Prisoners.
Gordon MS; Kinlock TW; Vocci FJ; Fitzgerald TT; Memisoglu A; Silverman B
J Subst Abuse Treat; 2015 Dec; 59():52-8. PubMed ID: 26299956
[TBL] [Abstract][Full Text] [Related]
11. Naltrexone and bupropion, alone or combined, do not alter the reinforcing effects of intranasal methamphetamine.
Stoops WW; Pike E; Hays LR; Glaser PE; Rush CR
Pharmacol Biochem Behav; 2015 Feb; 129():45-50. PubMed ID: 25459104
[TBL] [Abstract][Full Text] [Related]
12. Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study.
Ling W; Hillhouse MP; Saxon AJ; Mooney LJ; Thomas CM; Ang A; Matthews AG; Hasson A; Annon J; Sparenborg S; Liu DS; McCormack J; Church S; Swafford W; Drexler K; Schuman C; Ross S; Wiest K; Korthuis PT; Lawson W; Brigham GS; Knox PC; Dawes M; Rotrosen J
Addiction; 2016 Aug; 111(8):1416-27. PubMed ID: 26948856
[TBL] [Abstract][Full Text] [Related]
13. The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study.
Ray LA; Bujarski S; Courtney KE; Moallem NR; Lunny K; Roche D; Leventhal AM; Shoptaw S; Heinzerling K; London ED; Miotto K
Neuropsychopharmacology; 2015 Sep; 40(10):2347-56. PubMed ID: 25801501
[TBL] [Abstract][Full Text] [Related]
14. Separate and Combined Effects of Naltrexone and Extended-Release Alprazolam on the Reinforcing, Subject-Rated, and Cardiovascular Effects of Methamphetamine.
Marks KR; Lile JA; Stoops WW; Glaser PE; Hays LR; Rush CR
J Clin Psychopharmacol; 2016 Jun; 36(3):213-21. PubMed ID: 27043121
[TBL] [Abstract][Full Text] [Related]
15. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial.
Lee JD; McDonald R; Grossman E; McNeely J; Laska E; Rotrosen J; Gourevitch MN
Addiction; 2015 Jun; 110(6):1008-14. PubMed ID: 25703440
[TBL] [Abstract][Full Text] [Related]
16. Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial.
Anderson AL; Li SH; Markova D; Holmes TH; Chiang N; Kahn R; Campbell J; Dickerson DL; Galloway GP; Haning W; Roache JD; Stock C; Elkashef AM
Drug Alcohol Depend; 2015 May; 150():170-4. PubMed ID: 25818061
[TBL] [Abstract][Full Text] [Related]
17. Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: a preliminary blind-rater study.
Dannon PN; Lowengrub K; Musin E; Gonopolski Y; Kotler M
J Clin Psychopharmacol; 2005 Dec; 25(6):593-6. PubMed ID: 16282845
[TBL] [Abstract][Full Text] [Related]
18. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).
Apovian CM; Aronne L; Rubino D; Still C; Wyatt H; Burns C; Kim D; Dunayevich E;
Obesity (Silver Spring); 2013 May; 21(5):935-43. PubMed ID: 23408728
[TBL] [Abstract][Full Text] [Related]
19. A preliminary randomized clinical trial of naltrexone reduces striatal resting state functional connectivity in people with methamphetamine use disorder.
Kohno M; Dennis LE; McCready H; Schwartz DL; Hoffman WF; Korthuis PT
Drug Alcohol Depend; 2018 Nov; 192():186-192. PubMed ID: 30266003
[TBL] [Abstract][Full Text] [Related]
20. Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity.
Padwal R
Curr Opin Investig Drugs; 2009 Oct; 10(10):1117-25. PubMed ID: 19777400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
